BIOSIMILARS: MARKET ACCESS AND MARKET PENETRATION - A COMPARISON OF FRANCE AND GERMANY

被引：0
|
作者：
Freiberg, M. [1 ]
Schwarz, R. [1 ]
Khoury, C. [2 ]
机构：
[1] Quintiles Commercial Germany GmbH, Mannheim, Germany
[2] Quintiles Advisory Serv, St Ouen, France
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.553
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP16
引用
收藏
页码：A442 / A442
页数：1
相关论文
共 50 条
  • [31] More biosimilars reach the market in efforts to improve access and cut costs
    Abraham, Jame
    JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY, 2018, 16 (04): : E181 - E184
  • [32] EARLY ACCESS IN FRANCE: REASONS FOR REFUSALS AND IMPACT ON MARKET ACCESS
    Theuillon, T.
    Villemur, L.
    Le Mao, J.
    VALUE IN HEALTH, 2023, 26 (12) : S347 - S347
  • [33] EARLY ACCESS IN FRANCE: REASONS FOR REFUSALS AND IMPACT ON MARKET ACCESS
    Theuillon, T.
    Villemur, L.
    VALUE IN HEALTH, 2022, 25 (12) : S279 - S279
  • [34] BIOSIMILARS GAIN MARKET TRACTION
    Thayer, Ann M.
    CHEMICAL & ENGINEERING NEWS, 2015, 93 (43) : 28 - 29
  • [35] BIOSIMILARS: ACCESSING THE UK MARKET
    Das, P.
    VALUE IN HEALTH, 2015, 18 (07) : A558 - A558
  • [36] INFLIXIMAB AND ETANERCEPT BIOSIMILARS AND ORIGINATORS: LEARNINGS FROM REGIONAL MARKET DYNAMICS IN GERMANY
    Barcina, T.
    Moorkens, E.
    Vulto, A.
    Schulz, M.
    Gradl, G.
    Enners, S.
    Selke, G.
    Huys, I
    Simoens, S.
    VALUE IN HEALTH, 2020, 23 : S416 - S416
  • [37] MARKET POTENTIAL FOR PRINTING EQUIPMENT IN FRANCE, GERMANY AND ITALY
    LACKMAN, CL
    RIVISTA INTERNAZIONALE DI SCIENZE ECONOMICHE E COMMERCIALI, 1975, 22 (06): : 586 - 607
  • [38] MARKET PENETRATION
    DIRKMAN, JA
    RUMPF, TA
    IRLAND, LC
    JOURNAL OF FORESTRY, 1986, 84 (12) : 32 - 33
  • [39] COSTS SAVING GENERATED BY ANTI-TNF BIOSIMILARS MARKET PENETRATION IN FRANCE: AN ANALYSIS BASED ON FRENCH HEALTH INSURANCE OPEN DATA
    Denis, H.
    Gonzalez, J.
    Lafon, T.
    Vainchtock, A.
    Schmidt, A.
    VALUE IN HEALTH, 2023, 26 (12) : S163 - S164
  • [40] ORPHAN DRUGS IN FRANCE: KEY MARKET ACCESS INCENTIVES
    Mennezein, L.
    Avot, D.
    Laigle, V
    VALUE IN HEALTH, 2017, 20 (09) : A565 - A565
12345